Company Overview - Zoetis Inc. is a leader in the animal health sector, focusing on livestock and companion animals across seven major product categories, including parasiticides, vaccines, and anti-infectives [11] - The company caters to eight core species, which include both livestock (cattle, swine, poultry, fish, and sheep) and companion animals (dogs, cats, and horses) [11] Investment Ratings - Zoetis has a Zacks Rank of 3 (Hold) and a VGM Score of B, indicating a solid position in the market [12] - The company also has a Value Style Score of B, supported by attractive valuation metrics such as a forward P/E ratio of 16.5, making it appealing to value investors [12] Earnings Estimates - In the last 60 days, nine analysts have revised their earnings estimates upwards for fiscal 2026, with the Zacks Consensus Estimate increasing by $0.21 to $6.99 per share [12] - Zoetis has demonstrated an average earnings surprise of +6.3%, indicating a positive trend in earnings performance [12] Investment Consideration - With a solid Zacks Rank and strong Value and VGM Style Scores, Zoetis is recommended to be on investors' short lists for potential investment opportunities [13]

Core Insights - Diamond Hill Capital's "Mid Strategy" reported a strong performance in Q4 2025, with a return of 3.65% compared to the Russell Midcap Index's 0.16% [1] - The strategy's year-to-date return was 13.47%, outperforming the Russell Midcap Index's 10.60% [1] - AI-related spending was a significant driver in equity markets, although investor caution emerged in December 2025 [1] Company Overview: Zoetis Inc. (NYSE:ZTS) - Zoetis Inc. is a leader in the animal health market, focusing on medications, vaccines, and diagnostic products for both companion animals and livestock [3] - As of March 17, 2026, Zoetis Inc. shares closed at $121.68, with a market capitalization of approximately $53.624 billion [2] - The stock experienced a -5.77% return in the past month and a -25.69% decline over the past twelve months [2] Investment Positioning - Concerns regarding an arthritis drug for dogs have negatively impacted Zoetis Inc.'s share price, creating an opportunity for investment below intrinsic value estimates [3] - Despite its potential, Zoetis Inc. is not among the 40 most popular stocks among hedge funds, with 69 hedge fund portfolios holding the stock at the end of Q4, down from 72 in the previous quarter [4] - The company is viewed as having less upside potential compared to certain AI stocks, which are considered to carry less downside risk [4]

Core Insights - Jensen Investment Management's fourth-quarter investor letter for the "Jensen Quality Growth Equity Strategy" indicates that the strategy underperformed the S&P 500 Index in Q4 2025, returning -0.55% compared to the Index's 2.66% [1] - The underperformance was primarily attributed to the Industrials sector and the outperformance of low-quality stocks, highlighting a current market trend characterized by concentration in mega-cap technology [1] - The portfolio is strategically positioned to benefit from growth in AI and digital transformation while focusing on quality, cash generation, and durability for long-term shareholder returns [1] Company-Specific Insights - Zoetis Inc. (NYSE:ZTS), an animal health company, was highlighted in the investor letter, with its stock closing at $122.23 on March 05, 2026 [2] - Over the past month, Zoetis Inc. experienced a -4.07% return and a significant -28.26% decline over the past twelve months, with a market capitalization of approximately $53.866 billion [2] - The Quality Growth Investment Team liquidated positions in Zoetis Inc. along with Accenture (ACN) and Amphenol (APH) during the quarter [3]

Moderna agreed to pay $950 million to settle all litigation worldwide with Arbutus and Genevant Sciences over the company’s existing and future vaccines, with no future royalties owed https://t.co/olDh1H9zcB ...

Core Insights - Adaptive Biotechnologies Corporation (NASDAQ:ADPT) is recognized as a promising stock under $20 following its fiscal Q4 and full-year 2025 earnings release on February 5 [1] Group 1: Earnings and Ratings Updates - TD Cowen raised the price target for ADPT to $21 from $20 while maintaining a Buy rating after the fiscal Q4 earnings beat, citing positive signals from various drivers such as the shift to blood-based tests and EMR integrations [2] - BTIG also increased the price target for ADPT to $22 from $21, keeping a Buy rating, and noted that the company is performing strongly in the specialty labs sector [3] - JPMorgan updated its rating for ADPT, raising the price target to $21 from $20 and maintaining an Overweight rating [3] Group 2: Company Overview - Adaptive Biotechnologies Corporation is focused on developing an immune medicine platform, offering services and products like immunoSEQ, clonoSEQ, cellular therapy, and vaccines [4]

Company Overview - Elanco Animal Health Incorporated (NYSE:ELAN) specializes in veterinary medicine, providing products for the protection and treatment of pets and farm animals, including parasiticides, vaccines, therapeutics, and medicated feed additives [3]. Stock Performance - The stock has shown a remarkable performance, increasing by 137% over the past 12 months and nearly 17% since the beginning of 2026 [1]. - Following a strong quarterly report, Elanco's stock rose by 6.6% [1]. Financial Highlights - The company reported a 12% revenue growth, attributed to strong performance in both pet health and farm animal segments [1]. - Elanco achieved a 2-cent earnings beat, reporting earnings of 11 cents per share [1]. - Management provided a solid full-year forecast, indicating confidence in continued growth [1][2]. Management and Strategy - The management has successfully turned the company around, demonstrating effective strategies that have impressed analysts [2].

Core Insights - Zoetis Inc. (NYSE:ZTS) is recognized as a strong investment option in the pet stock sector, with a Hold rating reaffirmed by Barclays and a price target set at $136.00 [1] - The company reported fiscal Q4 2025 revenue of $2.4 billion, marking a 3% increase from fiscal Q4 2024, with net income reaching $603 million, or $1.37 per diluted share, reflecting increases of 4% and 6% respectively [1] - For the full year 2025, Zoetis reported total revenue of $9.5 billion, a 2% growth compared to 2024, with net income of $2.7 billion, or $6.02 per diluted share, showing increases of 8% and 10% respectively [2] Company Overview - Zoetis Inc. is a global leader in animal health, focusing on the development and commercialization of vaccines, medicines, and diagnostic products [3] - The company's operations are segmented into the United States and International markets, offering a diverse product portfolio that includes vaccines, parasiticides, and animal health diagnostics [3] - Zoetis specializes in products for eight core species, including companion animals (dogs, cats, horses), cattle, swine, livestock (sheep, fish), and poultry [3]

Core Viewpoint - Ovintiv Inc. (OVV) is set to report its fourth-quarter fiscal 2025 results on February 23, with earnings estimated at 98 cents per share and revenues at $1.95 billion [1]. Group 1: Previous Quarter Performance - In the last reported quarter, Ovintiv achieved adjusted earnings per share of $1.03, surpassing the Zacks Consensus Estimate of 97 cents, driven by increased plant condensate production and higher average realized natural gas prices [2]. - The company's total revenues for the third quarter were $2.1 billion, exceeding the Zacks Consensus Estimate by 6.1% [2]. - Ovintiv has beaten the Zacks Consensus Estimate in three of the last four quarters, with an average surprise of 11.06% [3]. Group 2: Upcoming Quarter Expectations - The Zacks Consensus Estimate for fourth-quarter fiscal 2025 earnings has remained unchanged over the past week, indicating a 27.41% year-over-year decrease, while the revenue estimate suggests a 10.96% increase from the previous year [3]. - Ovintiv's revenues are expected to decline in the upcoming quarter, primarily due to the company's focus on production volumes and market prices of energy commodities [4]. Group 3: Cost Management - Total operating expenses for the fourth quarter are projected to be $1.6 billion, reflecting a 28.2% decrease from the previous year's $2.2 billion [5]. - Production, mineral, and other taxes are anticipated to fall by 14.9% year-over-year to $63.9 million, while transportation and processing expenses are expected to decrease by 14.3% to $341.8 million [5]. - The cost of purchased products is forecasted to drop by 34% to $251.5 million, with depreciation, depletion, and amortization charges expected to be $433.9 million, marking a 20.4% reduction [6].

Core Viewpoint - Phibro Animal Health Corporation (NASDAQ:PAHC) is recognized as one of the seven cheap pharmaceutical stocks to consider for investment, particularly noted for its strong operational performance and positive financial outlook [1][2]. Financial Performance - For the fiscal second quarter ending December 31, 2025, Phibro reported a 21% increase in net sales to $373.9 million and a rise in net income to $27.5 million [4]. - Adjusted EBITDA increased by 41% to $68.1 million, while adjusted diluted EPS rose by 58% to $0.87 [4]. - The company has updated its fiscal 2026 net sales estimates to between $1.45 billion and $1.50 billion, with adjusted EBITDA projected between $245 million and $255 million, reflecting improved operating momentum [5]. Analyst Ratings - Morgan Stanley raised its price target for PAHC from $45 to $49, maintaining an Equal Weight rating, citing strong operational performance and effective execution in the Animal Health segment [3]. - The upgrade was influenced by significant margin expansion, a favorable fiscal 2026 forecast, and a profit beat in the second quarter [3].

Group 1 - Zoetis Inc. is identified as one of the cheap pharmaceutical stocks to buy according to hedge funds [1] - Bank of America raised its price target for Zoetis to $140 from $135 while maintaining a Neutral rating, supported by the company's fiscal 2026 projections and fourth-quarter performance [2] - The company reported an adjusted EPS of $1.48 for Q4 2025, exceeding the consensus forecast of $1.40, with sales increasing by 3% year-over-year to $2.4 billion [3] Group 2 - For fiscal year 2026, Zoetis projects revenue between $9.83 billion and $10.03 billion and adjusted EPS of $7.00 to $7.10, surpassing analyst forecasts [4] - The expected growth is driven by global operational gains, advancements in parasiticide and dermatology portfolios, and ongoing momentum in companion animal and cattle products [4] - Zoetis is a global leader in animal health, focusing on medicines, vaccines, and diagnostic products for livestock and companion animals [5]